Patent Leaderboard
USPTO Patent Rankings Data through Dec 31, 2025
Home › Combination of regorafenib and PD-1/PD-L1(2) inhibitors for treating cancer

Combination of regorafenib and PD-1/PD-L1(2) inhibitors for treating cancer

US Patent 11951166 · Granted Apr 9, 2024

Assignee

Inventors

View full patent text on Google Patents →

More Patents by These Inventors

Methods of treatment using CCR8 antibodies2024
2-heteroaryl-3-oxo-2,3-dihydropyridazine-4-carboxamides for the treatment of can2023
ILDR2 antagonists and combinations thereof2023
3-oxo-6-heteroaryl-2-phenyl-2,3-dihydropyridazine-4-carboxamides2023
2-phenylpyrimidine-4-carboxamides as AHR inhibitors2022
Combination of regorafenib and PD-1/PD-L1(2) inhibitors for treating cancer2022
Combination of regorafenib and PD-1/PD-L1(2) inhibitors for treating cancer2022
Combination of regorafenib and PD-1/PD-L1(2) inhibitors for treating cancer2022
Combination of regorafenib and PD-1/PD-L1(2) inhibitors for treating cancer2022
Combination of regorafenib and PD-1/PD-L1(2) inhibitors for treating cancer2022
Combination of regorafenib and PD-1/PD-L1(2) inhibitors for treating cancer2022
Sulphur substituted 3-oxo-2,3-dihydropyridazine-4-carboxamides2022